JNGHF — Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

OTC · Unknown · Unknown · CIK 2071868 · China
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
No quarterly fundamentals indexed for this ticker.

Yahoo Snapshot (yfinance, live)

Total Revenue
$32,564,369,408
EBITDA
$9,452,852,224
Free Cash Flow
$6,307,738,624
Enterprise Value
$10,296,649,728
Total Cash
$40,635,797,504
Total Debt
$67,474,744
Shares Out
Trailing EPS
Book Value
$1.40
ROE
14.5%
ROA
8.8%
Div Yield

Peers — same industry

TickerNameMarket CapLastDaily %
SPY SPDR S&P 500 ETF TRUST $692.88B $754.95
KLAC KLA CORP $302.43B $231.52
QQQ INVESCO QQQ TRUST, SERIES 1 $285.20B $725.51
IBM INTERNATIONAL BUSINESS MACHINES CORP $270.27B $287.56
KXIAY Kioxia Holdings Corporation/ADR $266.29B $48.66

News headlines (Yahoo Finance, 1h cache)

Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential
2026-07-10 13:58 · Yahoo
Eli Lilly's Market Cap Balloons Again On This IPO's Setback
2026-07-07 20:09 · Yahoo
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall
2026-07-07 18:49 · Yahoo
Kailera points to Phase III oral obesity drug data as it tees up Foundayo rivalry
2026-07-07 14:59 · Yahoo
Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial
2026-07-07 12:08 · Yahoo
Kailera says obesity pill succeeds in late-stage trial in China
2026-07-07 11:59 · Yahoo
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
2026-07-07 11:00 · Yahoo
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
2026-06-30 05:00 · Yahoo
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
2026-06-05 23:32 · Yahoo
Kailera’s three-pronged obesity shot shows promise in early trial
2026-05-27 11:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.